kentucky semaglutide intestinal paralysis lawsuit glp-1 stomach in GLP-1 medications are now at the center of glp-1 nausea class action in

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for several indications: type 2 diabetes mellitus, chronic weight management, and more recently, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity

Retarutide can be used for obesity research

GLP-1 RAs are effective and safe treatments for controlling blood sugar levels and reducing body weight, and evidence from large clinical trials also suggests that GLP-1 RAs may be renoprotective

Another option, Zepbound (tirzepatide), integrates dual action at two hormones for enhanced weight loss

Support for Lifestyle Changes Medical interventions are helpful, but real results come from habit change